What's Happening?
AbbVie has announced a $195 million investment to expand its active pharmaceutical ingredient (API) manufacturing capabilities in North Chicago, Illinois. This expansion is part of AbbVie's broader commitment to invest over $10 billion in the U.S. over the next decade. The new facility will enhance AbbVie's chemical synthesis capabilities, supporting the production of current and next-generation medicines in neuroscience, immunology, and oncology. Construction is set to begin in fall 2025, with the facility expected to be operational by 2027. This move will expand AbbVie's U.S. manufacturing footprint, which currently supports over 6,000 jobs across 11 sites.
AD
Why It's Important?
AbbVie's investment underscores its commitment to maintaining U.S. leadership in pharmaceutical innovation. By expanding its manufacturing capabilities, AbbVie aims to support future medical breakthroughs and deliver next-generation medicines. This investment is significant for Illinois, bolstering the state's biomanufacturing ecosystem and creating jobs. It reflects the state's strong workforce, infrastructure, and research institutions, which are attractive to global pharmaceutical leaders. The expansion will also contribute to the domestic production of critical medicines, enhancing the U.S.'s self-sufficiency in pharmaceutical manufacturing.
What's Next?
Construction of the new facility will begin in fall 2025, with operations expected to start in 2027. AbbVie will continue to expand its production of APIs, drug products, peptides, and medical devices in the U.S. over the next decade. This expansion is likely to attract further investments in Illinois and strengthen the state's position as a hub for pharmaceutical manufacturing. Stakeholders, including local government and industry leaders, may respond positively to the job creation and economic growth associated with this investment.
